Education
About Us
Working with TipRanks
Follow Us
Rigel Pharmaceuticals (CH:RIGL)
:RIGL
RIGL Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RIGL Stock 12 Month Forecast
There Are No Analyst Ratings for CH:RIGL In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
RIGL Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
CHF45.33
Buy
―
Reiterated
10/08/25
Rigel's Strategic Advancements and Financial Projections Justify Buy RatingValuation and impediments to achieving price target. We reiterate our Buy rating and $57 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from: (1) Tavalisse in ITP (62% contribution); and (2) AML contribution from Rezlidhia (27% contribution) and (3) Gavreto contribution for RET NSCLC and thyroid cancer (11% contribution) We highlight that we do not include additional indications Rezlidhia as well as pipeline assets, all representing potential upside potential to our valuation.
Jefferies
CHF16.26→CHF18.29
Hold
―
Reiterated
08/06/25
Piper Sandler
CHF18.29
Hold
―
Reiterated
07/28/25
Cantor Fitzgerald
CHF19.88→CHF15.91
Hold
―
Reiterated
03/05/25
B. Riley Securities
CHF15.91→CHF19.09
Hold
―
Reiterated
03/05/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
CHF45.33
Buy
―
Reiterated
10/08/25
Rigel's Strategic Advancements and Financial Projections Justify Buy RatingValuation and impediments to achieving price target. We reiterate our Buy rating and $57 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from: (1) Tavalisse in ITP (62% contribution); and (2) AML contribution from Rezlidhia (27% contribution) and (3) Gavreto contribution for RET NSCLC and thyroid cancer (11% contribution) We highlight that we do not include additional indications Rezlidhia as well as pipeline assets, all representing potential upside potential to our valuation.
Jefferies
CHF16.26→CHF18.29
Hold
―
Reiterated
08/06/25
Piper Sandler
CHF18.29
Hold
―
Reiterated
07/28/25
Cantor Fitzgerald
CHF19.88→CHF15.91
Hold
―
Reiterated
03/05/25
B. Riley Securities
CHF15.91→CHF19.09
Hold
―
Reiterated
03/05/25
Best Analysts Covering Rigel
1 Month
xxx
Success Rate
7/13 ratings generated profit
Average Return
+12.51%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +12.51% per trade.
3 Months
xxx
Success Rate
8/13 ratings generated profit
Average Return
+30.63%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +30.63% per trade.
1 Year
Success Rate
13/13 ratings generated profit
Average Return
+83.94%
reiterated a buy rating 28 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +83.94% per trade.
2 Years
xxx
Success Rate
11/13 ratings generated profit
Average Return
+76.48%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +76.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RIGL Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Oct 25
Strong Buy
4
3
3
3
3
Buy
10
9
14
11
14
Hold
4
2
4
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
14
21
18
21
Each month's total comprises the sum of three months' worth of ratings.
RIGL Stock Forecast FAQ
What is CH:RIGL’s average 12-month price target, according to analysts?
Currently, no data Available
What is CH:RIGL’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:RIGL, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rigel Pharmaceuticals a Buy, Sell or Hold?
Currently, no data Available
What is Rigel Pharmaceuticals’s share price target?
Currently, no data Available
What do analysts say about Rigel Pharmaceuticals?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Rigel Pharmaceuticals?
To buy shares of CH:RIGL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.